Skip to main content
Erschienen in: Obesity Surgery 5/2013

01.05.2013 | Original Contributions

Fasting and Meal-Induced CCK and PP Secretion Following Intragastric Balloon Treatment for Obesity

verfasst von: Elisabeth M. H. Mathus-Vliegen, Gerrit H. de Groot

Erschienen in: Obesity Surgery | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Satiety is centrally and peripherally mediated by gastrointestinal peptides and the vagal nerve. We aimed to investigate whether intragastric balloon treatment affects satiety through effects on fasting and meal-stimulated cholecystokinin (CCK) and pancreatic polypeptide (PP) secretion.

Methods

Patients referred for obesity treatment were randomised to 13 weeks of sham treatment followed by 13 weeks of balloon treatment (group 1; sham/balloon) or to twice a 13-week period of balloon treatment (group 2; balloon/balloon). Blood samples were taken for fasting and meal-stimulated CCK and PP levels at the start (T0) and after 13 (T1) and 26 (T2) weeks. Patients filled out visual analogue scales (VAS) to assess satiety.

Results

Forty-two patients (35 females, body weight 125.1 kg, BMI 43.3 kg/m2) participated. In group 1, basal CCK levels decreased but meal-stimulated response remained unchanged after 13 weeks of sham treatment. In group 2, basal and meal-stimulated CCK levels decreased after 13 weeks of balloon treatment. At the end of the second 13-week period, when group 1 had their first balloon treatment, they duplicated the initial 13-week results of group 2, whereas group 2 continued their balloon treatment and reduced meal-stimulated CCK release. Both groups showed reduced meal-stimulated PP secretions at T1 and T2 compared to T0. Changes in diet composition and VAS scores were similar. Improvements in glucose homeostasis partly explained the PP results.

Conclusions

The reduced CCK and PP secretion after balloon positioning was unexpected and may reflect delayed gastric emptying induced by the balloon. Improved glucose metabolism partly explained the reduced PP secretion. Satiety and weight loss were not adversely influenced by these hormonal changes.
Literatur
1.
Zurück zum Zitat Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida. Gastrointest Endosc. 1987;33:323–7.PubMedCrossRef Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida. Gastrointest Endosc. 1987;33:323–7.PubMedCrossRef
2.
Zurück zum Zitat Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 2007;(1):CD004931. Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 2007;(1):CD004931.
3.
Zurück zum Zitat Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4.PubMedCrossRef Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4.PubMedCrossRef
4.
Zurück zum Zitat Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.PubMedCrossRef Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.PubMedCrossRef
5.
Zurück zum Zitat Evans JT, Delegge MH. Intragastric balloon therapy in the management of obesity: why the bad wrap? JPEN J Parenter Enteral Nutr. 2011;35:25–31.PubMedCrossRef Evans JT, Delegge MH. Intragastric balloon therapy in the management of obesity: why the bad wrap? JPEN J Parenter Enteral Nutr. 2011;35:25–31.PubMedCrossRef
6.
Zurück zum Zitat Melton PM, Kissileff HR, Pi-Sunyer FX. Cholecystokinin (CCK-8) affects gastric pressure and ratings of hunger and fullness in women. Am J Physiol. 1992;263(2 Pt 2):R452–6.PubMed Melton PM, Kissileff HR, Pi-Sunyer FX. Cholecystokinin (CCK-8) affects gastric pressure and ratings of hunger and fullness in women. Am J Physiol. 1992;263(2 Pt 2):R452–6.PubMed
7.
Zurück zum Zitat Rigaud D, Trostler N, Rozen R, et al. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord. 1995;19:489–95.PubMed Rigaud D, Trostler N, Rozen R, et al. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord. 1995;19:489–95.PubMed
8.
Zurück zum Zitat Feinle C, Christen M, Grundy D, et al. Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil. 2002;14:205–13.PubMedCrossRef Feinle C, Christen M, Grundy D, et al. Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil. 2002;14:205–13.PubMedCrossRef
9.
Zurück zum Zitat Rushakoff RA, Goldfine ID, Beccaria LJ, et al. Reduced postprandial cholecystokinin (CCK) secretion in patients with non-insulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia. J Clin Endocrinol Metab. 1993;76:489–93.PubMedCrossRef Rushakoff RA, Goldfine ID, Beccaria LJ, et al. Reduced postprandial cholecystokinin (CCK) secretion in patients with non-insulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia. J Clin Endocrinol Metab. 1993;76:489–93.PubMedCrossRef
10.
Zurück zum Zitat Weickert MO, Möhlig M, Spranger J, et al. Effects of euglycemic hyerinsulinemia and lipid infusion on circulating cholecystokin. J Clin Endocrinol Metab. 2008;93:2328–33.PubMedCrossRef Weickert MO, Möhlig M, Spranger J, et al. Effects of euglycemic hyerinsulinemia and lipid infusion on circulating cholecystokin. J Clin Endocrinol Metab. 2008;93:2328–33.PubMedCrossRef
11.
Zurück zum Zitat Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.PubMedCrossRef Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.PubMedCrossRef
12.
Zurück zum Zitat Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2.PubMedCrossRef Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2.PubMedCrossRef
13.
Zurück zum Zitat Jansen JB, Lamers CB. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta. 1983;131:305–16.PubMedCrossRef Jansen JB, Lamers CB. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta. 1983;131:305–16.PubMedCrossRef
14.
Zurück zum Zitat Lamers CB, Diemel CM, van Leer E, et al. Mechanism of elevated serum pancreatic polypeptide concentrations in chronic renal failure. J Clin Endocrinol Metab. 1982;55:922–6.PubMedCrossRef Lamers CB, Diemel CM, van Leer E, et al. Mechanism of elevated serum pancreatic polypeptide concentrations in chronic renal failure. J Clin Endocrinol Metab. 1982;55:922–6.PubMedCrossRef
15.
Zurück zum Zitat Blundell J, de Graaf C, Hulshof T, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010;11:251–70.PubMedCrossRef Blundell J, de Graaf C, Hulshof T, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010;11:251–70.PubMedCrossRef
16.
Zurück zum Zitat Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ. 1990;300:230–5.PubMedCrossRef Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ. 1990;300:230–5.PubMedCrossRef
17.
Zurück zum Zitat Cunningham KM, Baker RJ, Horowitz M, et al. Use of technetium-99 m(V)thiocyanate to measure gastric emptying of fat. J Nucl Med. 1991;32:878–81.PubMed Cunningham KM, Baker RJ, Horowitz M, et al. Use of technetium-99 m(V)thiocyanate to measure gastric emptying of fat. J Nucl Med. 1991;32:878–81.PubMed
18.
Zurück zum Zitat French SJ. The effects of specific nutrients on the regulation of feeding behaviour in human subjects. Proc Nutr Soc. 1999;58:533–9.PubMedCrossRef French SJ. The effects of specific nutrients on the regulation of feeding behaviour in human subjects. Proc Nutr Soc. 1999;58:533–9.PubMedCrossRef
19.
Zurück zum Zitat Lieverse RJ, van Seters AP, Jansen JB, et al. Relationship between hunger and plasma cholecystokinin during weight reduction with a very low calorie diet. Int J Obes Relat Metab Disord. 1993;17:177–9.PubMed Lieverse RJ, van Seters AP, Jansen JB, et al. Relationship between hunger and plasma cholecystokinin during weight reduction with a very low calorie diet. Int J Obes Relat Metab Disord. 1993;17:177–9.PubMed
20.
21.
22.
Zurück zum Zitat Mion F, Napoleon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15:510–6.PubMedCrossRef Mion F, Napoleon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15:510–6.PubMedCrossRef
23.
Zurück zum Zitat Geliebter A, Melton PM, Gage D, et al. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr. 1990;51:584–8.PubMed Geliebter A, Melton PM, Gage D, et al. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr. 1990;51:584–8.PubMed
24.
Zurück zum Zitat Oesch S, Ruegg C, Fischer B, et al. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav. 2006;30(87):903–10.CrossRef Oesch S, Ruegg C, Fischer B, et al. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav. 2006;30(87):903–10.CrossRef
25.
Zurück zum Zitat Hill P, Garbaczewski L, Koppeschaar H, et al. Peptide and steroid hormones in subjects at different risk for diet-related diseases. Am J Clin Nutr. 1988;48(3 Suppl):782–6.PubMed Hill P, Garbaczewski L, Koppeschaar H, et al. Peptide and steroid hormones in subjects at different risk for diet-related diseases. Am J Clin Nutr. 1988;48(3 Suppl):782–6.PubMed
26.
Zurück zum Zitat Tomita T, Greeley Jr G, Watt L, et al. Protein meal-stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults. Pancreas. 1989;4:395–400.PubMedCrossRef Tomita T, Greeley Jr G, Watt L, et al. Protein meal-stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults. Pancreas. 1989;4:395–400.PubMedCrossRef
27.
Zurück zum Zitat Wisen O, Bjorvell H, Cantor P, et al. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept. 1992;39:43–54.PubMedCrossRef Wisen O, Bjorvell H, Cantor P, et al. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept. 1992;39:43–54.PubMedCrossRef
28.
Zurück zum Zitat Lieverse RJ, Masclee AA, Jansen JB, et al. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord. 1994;18:123–7. Lieverse RJ, Masclee AA, Jansen JB, et al. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord. 1994;18:123–7.
29.
Zurück zum Zitat Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol. 2007;58 Suppl 1:13–35.PubMed Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol. 2007;58 Suppl 1:13–35.PubMed
30.
Zurück zum Zitat Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord. 2003;27:1479–85.PubMedCrossRef Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord. 2003;27:1479–85.PubMedCrossRef
31.
Zurück zum Zitat Burhol PG, Jenssen TG, Jorde R, et al. Plasma cholecystokinin (CCK) before and after a jejunoileal bypass operation in obese patients with reference to appetite regulation. Int J Obes. 1984;8:233–6.PubMed Burhol PG, Jenssen TG, Jorde R, et al. Plasma cholecystokinin (CCK) before and after a jejunoileal bypass operation in obese patients with reference to appetite regulation. Int J Obes. 1984;8:233–6.PubMed
32.
Zurück zum Zitat Lassmann V, Vague P, Vialettes B, et al. Low plasma levels of pancreatic polypeptide in obesity. Diabetes. 1980;29:428–30.PubMedCrossRef Lassmann V, Vague P, Vialettes B, et al. Low plasma levels of pancreatic polypeptide in obesity. Diabetes. 1980;29:428–30.PubMedCrossRef
33.
Zurück zum Zitat Marco J, Zulueta MA, Correas I, et al. Reduced pancreatic polypeptide secretion in obese subjects. J Clin Endocrinol Metab. 1980;50:744–7.PubMedCrossRef Marco J, Zulueta MA, Correas I, et al. Reduced pancreatic polypeptide secretion in obese subjects. J Clin Endocrinol Metab. 1980;50:744–7.PubMedCrossRef
34.
Zurück zum Zitat Holst JJ, Schwartz TW, Lovgreen NA, et al. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes. 1983;7:529–38.PubMed Holst JJ, Schwartz TW, Lovgreen NA, et al. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes. 1983;7:529–38.PubMed
35.
Zurück zum Zitat Lawson MJ, Gehling RN, Butler RN, et al. Human pancreatic polypeptide release and gallbladder response after amino acid and cephal vagal stimuli in obese and non-obese subjects. Med Sci Res. 1987;15:183–4. Lawson MJ, Gehling RN, Butler RN, et al. Human pancreatic polypeptide release and gallbladder response after amino acid and cephal vagal stimuli in obese and non-obese subjects. Med Sci Res. 1987;15:183–4.
36.
Zurück zum Zitat Glaser B, Zoghlin G, Pienta K, et al. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res. 1988;20:288–92.PubMedCrossRef Glaser B, Zoghlin G, Pienta K, et al. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res. 1988;20:288–92.PubMedCrossRef
37.
Zurück zum Zitat Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124:1325–36.PubMedCrossRef Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124:1325–36.PubMedCrossRef
38.
Zurück zum Zitat Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides. 2007;28:459–63.PubMedCrossRef Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides. 2007;28:459–63.PubMedCrossRef
39.
Zurück zum Zitat Peterson HR, Rothschild M, Weinberg CR, et al. Body fat and the activity of the autonomic nervous system. N Engl J Med. 1988;318:1077–83.PubMedCrossRef Peterson HR, Rothschild M, Weinberg CR, et al. Body fat and the activity of the autonomic nervous system. N Engl J Med. 1988;318:1077–83.PubMedCrossRef
40.
Zurück zum Zitat Teff K. Learning hunger: conditioned anticipatory ghrelin responses in energy homeostasis. Endocrinology. 2006;147:20–2.PubMedCrossRef Teff K. Learning hunger: conditioned anticipatory ghrelin responses in energy homeostasis. Endocrinology. 2006;147:20–2.PubMedCrossRef
41.
Zurück zum Zitat Berger D, Floyd JC, Pek SB. The effect of treatment of type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon. Diabetologia. 1981;21:120–5.PubMedCrossRef Berger D, Floyd JC, Pek SB. The effect of treatment of type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon. Diabetologia. 1981;21:120–5.PubMedCrossRef
42.
Zurück zum Zitat Gingerich RL, Nagulesparan L, Bennion L, et al. Pancreatic polypeptide in Pima Indians: the influence of obesity and diabetes. Metabolism. 1985;34:25–9.PubMedCrossRef Gingerich RL, Nagulesparan L, Bennion L, et al. Pancreatic polypeptide in Pima Indians: the influence of obesity and diabetes. Metabolism. 1985;34:25–9.PubMedCrossRef
43.
Zurück zum Zitat Weyer C, Salbe AD, Lindsay RS, et al. Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism. 2001;50:223–30.PubMedCrossRef Weyer C, Salbe AD, Lindsay RS, et al. Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism. 2001;50:223–30.PubMedCrossRef
44.
Zurück zum Zitat Vozarova de Courten B, Weyer C, et al. Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes. 2004;53:663–71.PubMedCrossRef Vozarova de Courten B, Weyer C, et al. Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes. 2004;53:663–71.PubMedCrossRef
45.
Zurück zum Zitat Powley TL, Phillips RJ. Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav. 2004;82:69–74.PubMedCrossRef Powley TL, Phillips RJ. Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav. 2004;82:69–74.PubMedCrossRef
46.
Zurück zum Zitat Kissileff HR, Carretta JC, Geliebter A, et al. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol. 2003;285:R992–8.PubMed Kissileff HR, Carretta JC, Geliebter A, et al. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol. 2003;285:R992–8.PubMed
47.
Zurück zum Zitat Jones KL, Doran SM, Hveem K, et al. Relation between postprandial satiation and antral area in normal subjects. Am J Clin Nutr. 1997;66:127–32.PubMed Jones KL, Doran SM, Hveem K, et al. Relation between postprandial satiation and antral area in normal subjects. Am J Clin Nutr. 1997;66:127–32.PubMed
48.
Zurück zum Zitat Sturm K, Parker B, Wishart J, et al. Energy intake and appetite are related to antral area in healthy young and older subjects. Am J Clin Nutr. 2004;80:656–67.PubMed Sturm K, Parker B, Wishart J, et al. Energy intake and appetite are related to antral area in healthy young and older subjects. Am J Clin Nutr. 2004;80:656–67.PubMed
49.
Zurück zum Zitat Mundt MW, Hausken T, Smout AJ, et al. Relationships between gastric accommodation and gastrointestinal sensations in healthy volunteers. A study using the barostat technique and two- and three-dimensional ultrasonography. Dig Dis Sci. 2005;50:1654–60.PubMedCrossRef Mundt MW, Hausken T, Smout AJ, et al. Relationships between gastric accommodation and gastrointestinal sensations in healthy volunteers. A study using the barostat technique and two- and three-dimensional ultrasonography. Dig Dis Sci. 2005;50:1654–60.PubMedCrossRef
Metadaten
Titel
Fasting and Meal-Induced CCK and PP Secretion Following Intragastric Balloon Treatment for Obesity
verfasst von
Elisabeth M. H. Mathus-Vliegen
Gerrit H. de Groot
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 5/2013
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-012-0834-6

Weitere Artikel der Ausgabe 5/2013

Obesity Surgery 5/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.